{"name":"Compugen Ltd","slug":"compugen-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"COM701","genericName":"COM701","slug":"com701","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"COM701","genericName":"COM701","slug":"com701","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQRmRBMGVzOHN1dTBxSEZfcm1MYWVHRV9BN1JIdFZpaldBdGswdXhwQWxmS0dNT1RHMkZfNUhieWJRX3R6RzdMSGFDNlY0Uzc1N25vNXlUZWdPQk9YQktZZ1EzWFljVHZGNHhlMEZNdHZQcTVrSV9PZTJjRWFMRVMtV05yNkE3SFhyS1FUc0JwcW1ad2JLWGFMT0FJWm5nQVpGTU91WlNvMmFvRUhPcXJ2bnhHbllwdXRaTUFvbkRn?oc=5","date":"2026-03-02","type":"pipeline","source":"Seeking Alpha","summary":"Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement (CGEN) - Seeking Alpha","headline":"Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement (CGEN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOaTZqSVJWa19kLXM0cTFpcUJvbGpCZDU4YVYxTHhoV1djaEQtVndIc2otTldDb21sQmdadmtUUGp2aXJMQTNzUUVoem5pMWJxd0E3OWpvWUV4QkIzd25EeDg0ZHpKLUdIdy1yR3Mxd2h2YTh0cHMzUWU4OFhqa2Q0UlgxZElHS3AxNzVQQzFOYVIyOGJLejhoZndzV1pjQklpak1KSnNzeE1qMUhXQXNjemkxdTFXQmdvd1Vidg?oc=5","date":"2026-02-12","type":"pipeline","source":"Stock Titan","summary":"30-year healthcare strategist joins Compugen cancer board - Stock Titan","headline":"30-year healthcare strategist joins Compugen cancer board","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-07","type":"earnings","source":"simplywall.st","summary":"There's No Escaping Compugen Ltd.'s (NASDAQ:CGEN) Muted Revenues Despite A 25% Share Price Rise - simplywall.st","headline":"There's No Escaping Compugen Ltd.'s (NASDAQ:CGEN) Muted Revenues Despite A 25% Share Price Rise","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxOeHA4azZFM3JvWWRSUjY1ZUlLelNLdGJhaWhUSEltR2xrYnV6eG9LYVg4U2x0MG1UdC0wSnZCR29fckYzdDQtRWMtdG1XYjBVNmxSNm5QSjlYSjU2Rm1jMkNwSmxKREViblNla2hGdEI3OXluZ1Q3QWtDOVlCYUo0VzFraDZZSG53XzI1VkNGOFJqTG5wZm9KTUdVLVNxVW1nUEFqSTJ1MlZibEtEOVpxZ2xISXBFVC00OVYybkFpMlJkZW9RUFVGSUVPeDBSUERqVWNmNlRWUTg2d9IB3wFBVV95cUxQdWVTUTQzdDRzVG1aWDdrV3ZveTZVWjFBcHU2T1NkUmJxb0VvWGdjbVJhcDlIdkFoZkQ0NllpWXJpcV9YeUJIX1E0Vm1RTzZ3bzZTSXNRREwxcFVMUnV2ZzdIUXNudTd3TVRpMlNmWm9hRUozdUp1YzJ6cVd1MnRSbWRxSUs0dk5DRlVRUHpaN3pwZF9wM2NmNDR4RnZtZEtDeG44SmZ4VGxiUElFN0ladmFBQmtVN1J3cXlVYnZFa21vVEprRlp5Tkp5aHVKVHJXRU1CcjVycHhJX3dXckVj?oc=5","date":"2025-05-25","type":"pipeline","source":"simplywall.st","summary":"Analysts Just Shaved Their Compugen Ltd. (NASDAQ:CGEN) Forecasts Dramatically - simplywall.st","headline":"Analysts Just Shaved Their Compugen Ltd. (NASDAQ:CGEN) Forecasts Dramatically","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFA1QWo4czdlc0JuWFAxMTFKY0VGNFRfV0ZfMmtQb0FkMWlBN0xuT1ZuSE1WNjVsN1ROYzV3eXZQT0hNcjI2OU1XRWNnRERBN2sxblRJT2FucEJnTkpQSWhWWnZSVGlXdjg4ZEhuTVRxT0U4MXdCajBKZGZR?oc=5","date":"2025-05-13","type":"pipeline","source":"The Pharma Letter","summary":"Eran Ophir lined up to be Compugen CEO - The Pharma Letter","headline":"Eran Ophir lined up to be Compugen CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPd01pMjQ1azdhSjJVQ0RiSEhmTlluQnFncm5aMEQ4MzE2QXZuaVlvWk9hcWJyOV9xb05VcVRxOTI4UC01RzJ0UC1EY2FwbzBXaXgyVnJTMEdiMGtvakl4aEdHVkIyUThPNG1YZjdhSlpwaThGWVk3R0xvZUxnMkExX3dkdWpfSGk0NmlBWXBKV2c1Y1pYX0R4dlVvdFk4SVp4YnJQYjY3eFo5VkNYenhNRGw3aGhNUnM?oc=5","date":"2024-05-15","type":"pipeline","source":"PR Newswire","summary":"Compugen Appoints David Silberman as Chief Financial Officer - PR Newswire","headline":"Compugen Appoints David Silberman as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPNTJ4LUF3RmVrYXk4VWZzRWg1S2drdy1mWUtMZzBCOXpza0FsbEg2YWZLcVZySWZlcTJQbF8xZVphNkFGTHNNNjBHRWxWTlc0UjFBX2lxVmpLbmFkY1E0Ni0zcW95QldRVnpsY0QwWGRaZFh6UEdTT0YxWENhajFNNlVVMkp3UDlLZndpRmo4TVVQM1k?oc=5","date":"2024-03-13","type":"pipeline","source":"European Medical Journal","summary":"5 minutes with Anat Cohen-Dayag, CEO, Compugen - European Medical Journal","headline":"5 minutes with Anat Cohen-Dayag, CEO, Compugen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOa3VRY0VrZjh6anZZYVVfdG5NY3hfUEF4ak1sN19KdWRqMUJ1V25GODk2WE9IRzdFaE8wRGF6X3dBUjFvbmZzOWtLbkMxOHlOZFRmUWlPU0EybldIRUhJX2FTQ05KaGd5SWk4UkFqVlh6elB2OFI3b3hXem9hNjZUV3FURzFfZzBkcUt3NWlrRjcyZW9Ia1Qw?oc=5","date":"2024-02-21","type":"pipeline","source":"citybiz","summary":"AdhereTech Appoints Paul Sekhri to Board of Directors - citybiz","headline":"AdhereTech Appoints Paul Sekhri to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNSGpNcUxJa2FmRUJrQ2paS0hhOXlKMXp0MDM2MDRFczlTc2xOelZsWmlIR1Z5NUFPalgxQUJzVzhad25mSlZxVEhJMjAyekxKbDRBUVpSc2pUVE92ZHJMbnUxMjF0YkRBWVJXdlNzSVNtWXIwaXl3NFJnUEdieWlUTTRVQ3RxVXNEZjlkZGFubllwSnhHU1hJckNBSzZUMEVMbHRHZGtjQTFDck1zWTJQT0ZqSkN2d3BZaXVOOF9FdjhOUHI0NEE0YXc3MkJ4SXdBR0E?oc=5","date":"2024-02-15","type":"pipeline","source":"PR Newswire","summary":"Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer - PR Newswire","headline":"Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxQM2JxUGp1dG9qQVJGMnJsMU5NaENkbHpHVDdEbno4T2VlUmpyTTNOLTVIdFpyNm1QMG9IZThXOU1CTjl0ZUxIaWdCSk1vLVpoRUdsVm9KZDlJSFpnTTRNTmFFcUVMSV9JU1cwVW1vSWtIRGQ5Z1F2bHJ5WkE3RVNiLXpMWG81MmVaU0FVYmN1MHI2eGY5TEtPRVlHMnZSaHgxQ0dLQUkwRlVhc1RDd1Vib1F2SXpmUEZZalhwVEdMU2s4SFNLR2FWRXRtVVhsNHEyNGZ1RmFuZ2JCb0pBcVc3bUQ4MXhoTVZpM0UyS0Fxaw?oc=5","date":"2023-12-19","type":"deal","source":"businesswire.com","summary":"Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program - businesswire.com","headline":"Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE55V0hydWNuOGUtM2Y1QnFEUEFwaGs3c19ZV3NOSF9tRUo3bUJxY0NyZ1kzanQ4Y0ZfczFVTFk1RmFhbU5Ra3ltbWJ0WlNrMDBWTU9EOE9pc1ZMZnAxT2xN?oc=5","date":"2022-04-13","type":"pipeline","source":"nature.com","summary":"Compugen: from code to cure - nature.com","headline":"Compugen: from code to cure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNaWM0ZHhHU1N1SzNwSWRCTFBwZ2pPdHRUYXJ1cjJleE53WEh4R2QwMS1yTEhaTHRTSUFUS09GakpTN2traEZQb044RWhKT3pfekVPa2FLblBFOGxMQTY4TDh5MUwtRUNNLTJ1NUNEQVpFUjk5ZlNMb3BNVjI1Mm9Vek5xYkZaR1hJM3ZxYw?oc=5","date":"2018-04-02","type":"deal","source":"Fierce Biotech","summary":"AstraZeneca, Compugen sign immuno-oncology deal - Fierce Biotech","headline":"AstraZeneca, Compugen sign immuno-oncology deal","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}